Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition

Although the BRAF inhibitors dabrafenib and vemurafenib have both proven successful against BRAF‐mutant melanoma, there seem to be differences in their mechanisms of action. Here, we show that dabrafenib is more effective at inhibiting the growth of NRAS‐mutant and KRAS‐mutant cancer cell lines than...

Descripción completa

Detalles Bibliográficos
Autores principales: Phadke, Manali, Remsing Rix, Lily L., Smalley, Inna, Bryant, Annamarie T., Luo, Yunting, Lawrence, Harshani R., Schaible, Braydon J., Chen, Yian A., Rix, Uwe, Smalley, Keiran S. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748485/
https://www.ncbi.nlm.nih.gov/pubmed/29112787
http://dx.doi.org/10.1002/1878-0261.12152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748485/
https://www.ncbi.nlm.nih.gov/pubmed/29112787
http://dx.doi.org/10.1002/1878-0261.12152

Ejemplares similares